#Immuno-Oncology Market Scope

[soumyafwr]

Immuno-Oncology Market Size, Analysis and Forecast 2031

[mitalipingale]

https://biiut.com/read-blog/45985_immuno-oncology-drugs-market-analysis-size-share-and-forecast-2031.html

The Immuno Oncology Drugs Market in 2023 is US$ 20.24 billion, and is expected to reach US$ 71.18 billion by 2031 at a CAGR of 17.02%.

[amrutatbrc1]

Clinical Oncology Next Generation Sequencing Market 2024 : Size, Growth Rate, Business Module, Product Scope, Regional Analysis And Expansions 2033

The clinical oncology next generation sequencing global market report 2024 from The Business Research Company provides comprehensive market statistics, including global market size, regional shares, competitor market share, detailed segments, trends, and opportunities. This report offers an in-depth analysis of current and future industry scenarios, delivering a complete perspective for thriving in the industrial automation software market.

Clinical Oncology Next Generation Sequencing Market, 2024 report by The Business Research Company offers comprehensive insights into the current state of the market and highlights future growth opportunities.

Market Size - The clinical oncology next generation sequencing market size has grown rapidly in recent years. It will grow from $0.45 billion in 2023 to $0.52 billion in 2024 at a compound annual growth rate (CAGR) of 15.5%. The growth in the historic period can be attributed to genomic research advances, cancer biomarker discovery, technological advancements, regulatory approvals.

The clinical oncology next generation sequencing market size is expected to see rapid growth in the next few years. It will grow to $0.86 billion in 2028 at a compound annual growth rate (CAGR) of 13.2%. The growth in the forecast period can be attributed to growing cancer incidence, precision medicine, immuno-oncology, liquid biopsies. Major trends in the forecast period include comprehensive genomic profiling (cgp), immuno-oncology, tumor evolution and heterogeneity, ai and machine learning.

Order your report now for swift delivery @ https://www.thebusinessresearchcompany.com/report/clinical-oncology-next-generation-sequencing-global-market-report

The Business Research Company's reports encompass a wide range of information, including:

1. Market Size (Historic and Forecast): Analysis of the market's historical performance and projections for future growth.

2. Drivers: Examination of the key factors propelling market growth.

3. Trends: Identification of emerging trends and patterns shaping the market landscape.

4. Key Segments: Breakdown of the market into its primary segments and their respective performance.

5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.

6. Macro Economic Factors: Assessment of broader economic elements impacting the market.

Market Drivers - The rise in the number of cancer cases across the globe is likely to contribute to the growth of the clinical oncology next-generation sequencing market during the forecast period. According to the American Cancer Society, there were 1.9 million new cases and 0.6 million cancer deaths in 2021 in the USA. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43% of all the new cancer cases. Therefore, the rise in cancer incidence rate globally is anticipated to boost the demand for the growth of the clinical oncology next-generation sequencing market.

The clinical oncology next generation sequencing market covered in this report is segmented –

1) By Technology: Ion Semiconductor Sequencing, Pyro-Sequencing, Synthesis Sequencing, Real Time Sequencing, Ligation Sequencing, Reversible Dye Termination Sequencing, Nano-Pore Sequencing 2) By Application: Screening, Companion Diagnostics, Other Diagnostics 3) By End User: Hospital Laboratories, Clinical Research Organizations, Diagnostic laboratories

Get an inside scoop of the clinical oncology next generation sequencing market, Request now for Sample Report @ https://www.thebusinessresearchcompany.com/sample.aspx?id=3344&type=smp

Regional Insights - North America was the largest region in the clinical oncology next-generation sequencing market in 2023. Asia-Pacific was the second largest region in the clinical oncology next-generation sequencing market. The regions covered in the clinical oncology next generation sequencing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Key Companies - Major companies operating in the clinical oncology next generation sequencing market include Thermo Fisher Scientific, Oxford Nanopore Technologies Ltd., QIAGEN N.V., Myriad Genetics Inc., Illumina Inc., F. Hoffmann-La Roche Ltd., PerkinElmer Inc., Agilent Technologies Inc., Pacific Biosciences of California Inc., Caris Life Sciences, Paradigm Diagnostics, GATC Biotech AG, Macrogen Inc., DNASTAR Inc., Exosome Diagnostics Inc., Biomatters Ltd., Partek Inc., Foundation Medicine Inc., Becton Dickinson and Company (BD), Takara Bio Inc., Creative Biolabs, Mogene LC, Knome Inc., Genomatix Software GmbH, CLC bio, GnuBIO Inc., Bio-Rad Laboratories Inc., BGI Genomics Co. Ltd., Guardant Health Inc., Invitae Corporation, Natera Inc., NeoGenomics Laboratories Inc., Sysmex Corporation, Veracyte Inc., Zymo Research Corporation, ArcherDX Inc., Cepheid, Karius Inc., OncoDNA S.A., Personal Genome Diagnostics Inc., PierianDx Inc.

Table of Contents 1. Executive Summary 2. Clinical Oncology Next Generation Sequencing Market Report Structure 3. Clinical Oncology Next Generation Sequencing Market Trends And Strategies 4. Clinical Oncology Next Generation Sequencing Market – Macro Economic Scenario 5. Clinical Oncology Next Generation Sequencing Market Size And Growth ….. 27. Clinical Oncology Next Generation Sequencing Market Competitor Landscape And Company Profiles 28. Key Mergers And Acquisitions 29. Future Outlook and Potential Analysis 30. Appendix

Contact Us:

The Business Research Company

Europe: +44 207 1930 708

Asia: +91 88972 63534

Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

[priteshwemarketresearch]

Ipilimumab Market by Platform, Type, Technology and End User Industry Statistics, Scope, Demand with Forecast 2034

Global Ipilimumab Market: A Growing Force in Cancer Immunotherapy

Ipilimumab Market under the brand name Yervoy, is a monoclonal antibody used in the treatment of various types of cancer. It works by blocking programmed cell death protein 1 (PD-1), a protein that helps cancer cells evade the immune system. Ipilimumab is often used in combination with other treatments, such as chemotherapy or other immune checkpoint inhibitors.

Request Free Sample PDF:https://wemarketresearch.com/reports/request-free-sample-pdf/lpilimumab-market/1500

Market Dynamics:

The global ipilimumab market is driven by several factors:

Increasing Prevalence of Cancers: The rising incidence of cancers worldwide, particularly melanoma, is a key driver of market growth.

Drug Efficacy: Ipilimumab has demonstrated significant efficacy in clinical trials, leading to increased adoption in treatment regimens.

Expanding Indications: Ongoing research is exploring the potential of ipilimumab for treating other cancer types, such as renal cell carcinoma and non-small cell lung cancer.

Competitive Landscape: While ipilimumab faces competition from other immune checkpoint inhibitors, its unique properties and clinical data have contributed to its market success.

Market Segmentation

The ipilimumab market can be segmented based on:

Cancer Type: Melanoma, renal cell carcinoma, non-small cell lung cancer, and other indications.

Treatment Stage: First-line, second-line, and third-line treatments.

Geography: North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa.

Market Challenges and Opportunities

High Drug Cost: The price of ipilimumab can be a significant barrier for patients and healthcare systems.

Reimbursement Challenges: Gaining insurance coverage for ipilimumab can be complex in some regions.

Emerging Competitors: The development of new immune checkpoint inhibitors and targeted therapies poses competition to ipilimumab.

Expanding Indications: The potential for ipilimumab to be approved for additional cancer types represents a significant growth opportunity.

Opportunities in the Ipilimumab Market

Expanding Indications: Ongoing research into new cancer indications provides ample opportunities for market expansion. Trials exploring the efficacy of ipilimumab in cancers like prostate cancer and other solid tumors could lead to new approvals and increased market potential.

Patient Access and Affordability: Efforts to improve patient access and reduce treatment costs could open new avenues for market growth. Innovations in pricing models, patient assistance programs, and insurance coverage can make ipilimumab more accessible to a broader patient population.

Biomarker Development: The development of biomarkers to identify patients who are most likely to benefit from ipilimumab treatment could enhance its clinical use and market adoption. Personalized medicine approaches can optimize treatment regimens and improve patient

Challenges Facing the Market

High Cost of Treatment: Ipilimumab, like many immunotherapies, is associated with a high cost. This can limit its accessibility and impact overall market growth. Addressing cost-related challenges and finding ways to make treatments more affordable is crucial.

Competitive Landscape: The immuno-oncology field is highly competitive, with numerous companies developing similar checkpoint inhibitors and combination therapies. Staying ahead in terms of innovation and clinical efficacy is essential for maintaining market position.

Adverse Effects and Tolerability: Managing the side effects of ipilimumab, which can include immune-related adverse events, remains a challenge. Ensuring that patients can tolerate the treatment while effectively managing these side effects is vital for sustained market success.

Competitive Strategies and Market Positioning

Strategic Partnerships: Collaborations between pharmaceutical companies, research institutions, and oncology centers are pivotal in advancing ipilimumab’s market reach. Strategic partnerships can lead to joint research efforts, shared resources, and enhanced market access.

Innovation and Differentiation: In a competitive Ipilimumab Market, differentiating ipilimumab from other immune checkpoint inhibitors is essential. Innovations such as novel drug formulations, improved delivery methods, or adjunctive therapies can enhance its appeal. Companies are also investing in next-generation immunotherapies to maintain a competitive edge.

Marketing and Education: Effective marketing strategies and educational initiatives play a key role in promoting ipilimumab. Awareness campaigns aimed at both healthcare professionals and patients can drive informed decision-making and increase adoption rates. Educational programs about the benefits, side effects, and management of ipilimumab are crucial for its successful integration into clinical practice.

Research and Clinical Advancements

Innovative Research: Cutting-edge research into the mechanisms of action of ipilimumab and its interactions with the immune system is advancing our understanding of its therapeutic potential. Research into biomarkers that predict response and resistance to ipilimumab can lead to more personalized treatment approaches and improved outcomes.

Combination Therapies: Ongoing clinical trials are exploring combinations of ipilimumab with other therapies, such as chemotherapy, radiotherapy, and targeted agents. These studies aim to enhance efficacy, reduce resistance, and improve patient outcomes. Positive results from these trials could expand the indications and Ipilimumab Market potential of ipilimumab.

Real-World Evidence: Collecting real-world evidence (RWE) is increasingly important in demonstrating the effectiveness of ipilimumab outside controlled clinical settings. RWE can provide insights into long-term outcomes, safety profiles, and patient experiences, supporting broader adoption and informed decision-making.

Future Outlook

The global ipilimumab market is expected to continue growing, driven by advancements in cancer research, expanding indications, and increased patient access. As the drug's efficacy is further established and reimbursement challenges are addressed, the market is poised for significant expansion.

The ipilimumab market is poised for continued growth, driven by advancements in cancer research, combination therapies, and expanding indications. While challenges such as cost and competition exist, the opportunities for innovation and patient access offer promising prospects. As the landscape of cancer treatment evolves, ipilimumab is likely to remain a key player in the immunotherapy arena, contributing to the ongoing quest for more effective and personalized cancer treatments.

Conclusion:

The ipilimumab market stands at a crossroads of significant potential and ongoing challenges. As a cornerstone of immuno-oncology, ipilimumab has already demonstrated its transformative impact on cancer treatment. However, its journey is far from complete, and the path forward involves navigating a landscape shaped by rapid advancements, regulatory complexities, and evolving patient needs.

[rohans18]

Immuno-Oncology Clinical Trials Market Size, Reports, Demands, Share - Forecast 2029

Global Immuno-Oncology Clinical Trials Market, By Phase (Phase I, Phase I, Phase III, Phase IV), Design (Interventional Trials, Observational Trials, Expanded Access Trials), Indication (Solid Tumours, Hematological Cancer), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

An expert team performs systematic, object-oriented and complete market research study to provide the facts associated with any subject in the field of marketing via Immuno-Oncology Clinical Trials marketing report. The report has a lot to offer to both established and new players in the Immuno-Oncology Clinical Trials industry with which they can completely understand the market. SWOT analysis and Porter’s Five Forces analysis methods are used wherever applicable, while generating this report. One of the most important parts of an international Immuno-Oncology Clinical Trials market report is competitor analysis with which businesses can estimate or analyse the strengths and weaknesses of the competitors.

Key Players

The major players covered in the Immuno-Oncology Clinical Trials market report are Merck Sharp & Dohme Corp., Northeast Pharmaceutical Group Co., Ltd., Cayman Chemical, Tokyo Chemical Industry Co. Ltd., ,Kaiyuan Hengtai Nutrition Co., Ltd., ChengDa PharmaCeuticals Co.,Ltd., Avanscure Lifesciences Pvt. Ltd., Biosint SpA, Maxsun Industries, MANUS AKTTEVA BIOPHARMA LLP, Huanggang Huayang Pharmaceutical Co., Ltd., Merck KGaA, Viachem Limited and Spectrum Chemical Manufacturing Corp., among other domestic and global players.  Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-immuno-oncology-clinical-trials-market

With the help of credible Immuno-Oncology Clinical Trials market analysis report, businesses can make out the reaction of the consumers to an already existing product in the market. The report includes estimations of recent state of the market, CAGR values, market size and market share, revenue generation, and necessary changes required in the future products. A wide-ranging competitor analysis helps build superior strategies of production, improvement in certain product, its advertising or marketing and promotion for the business. Exhaustive and comprehensive market study performed in the wide ranging Immuno-Oncology Clinical Trials market report offers current and forthcoming opportunities that put light on the future market investment.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Immuno-Oncology Clinical Trials Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Size

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 More Reports:

Diuretic Drugs Market

Patient Engagement Technology Market

Healthcare Business Intelligence Market

Chinese Hamster Ovary cells (CHO) Market

Anti-cancer Drug Market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[healthcare-domain]

Microscopy Market: Current Progress, Growth Drivers, challenges, and Future Development

Nanotechnology is the science and technology of functional systems at the molecular scale. It is a multidisciplinary field covering a vast array of scientific fields, such as chemistry, biology, physics, materials science, and engineering. Structural characterization is an essential step in nonmaterial research, in which microscopes are extensively used.

Since nanostructures are too small to be visualized with conventional optical microscopes, advanced microscopes and tools are preferred that adequately characterize their structure and surface in detail at the molecular and atomic levels. Hence, the application of microscopy has increased in nanotechnology. Microscopes are also widely used in regenerative medicine research.

Regenerative medicine includes the generation and use of therapeutic stem cells, skin cells, and tissues, along with tissue engineering, for the production of functional organs. The regenerative medicine industry has been witnessing rapid growth in the past few years.

Currently, Microscopy Market is projected to grow from USD 7.2 billion in 2022 to USD 9.5 billion by 2027, at a CAGR of 5.8% from 2022 to 2027, according to a new report by MarketsandMarkets™. Factors such as advancement in technology of microscopes, growing interest of nanotechnology and regenerative medicines, better regulatory procedures along with growing application scope and high demand from key end users are driving the market growth. Moreover, high demand from the healthcare sector and the rapidly growing semiconductor industry are also among the key factors boosting the market growth.

Request for assumptions & how numbers were triangulated.

https://www.marketsandmarkets.com/requestsampleNew.asp?id=546

Market Growth Drivers

Favorable funding scenario for R&D in microscopy

Technological advancements in microscopes

Increased focus on nanotechnology and regenerative medicine

Market Growth Opportunities

Increasing application areas of microscopy

Growth opportunities in emerging markets

Integration of microscopy with spectroscopy

Market Challenges

Availability of open-source microscopy software

Industry Trends

Development of portable sequencing technologies

The major companies in the microscopy market include Carl Zeiss (Germany), Danaher Corporation (US), Thermo Fisher Scientific (US), Nikon (Japan), Bruker Corporation (US), Olympus (Japan), Oxford Instruments (UK), JEOL (Japan), and Hitachi High-Technologies (Japan), among others.

The industrial users segment accounted for the largest share of the microscopy market. Pharma-biopharma companies and CRO’s is the second fastest growing end-user segment. Factors such as continous and increasing R&D and manufacturing to meet the global demand for medicines, medical innovations such as precision medicine, cell and gene therapy and immuno-oncology are driving the growth of this end user segment.

Download an Illustrative Overview:

https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=399

Report Objectives:

To define, describe, and forecast the microscopy market based on type, product, application, end user, and region

To provide detailed information regarding the major factors influencing the growth of the global microscopy market (such as drivers, restraints, challenges, opportunities, and regulatory landscape, among others)

To strategically analyze micromarkets with respect to individual growth trends, prospects, and contributions to the global microscopy market

To analyze the opportunities in the global microscopy market for stakeholders and provide details of the competitive landscape for market leader

To profile key global players and comprehensively analyze their market shares and core competencies

To provide a five-year forecast for various market segments in terms of revenue with respect to five main regions, namely, North America (includes the US and Canada), Europe (includes Germany, the UK, France, Italy, and Spain), Asia Pacific (includes Japan, China, India, Australia, and South Korea), Latin America (includes Brazil and Mexico), and the Middle East & Africa

Recent Developments

In July 2021, Carl Zeiss introduced the ZEISS DeepRecon Pro and ZEISS PhaseEvolve reconstruction technologies in the ZEISS Xradia 3D X-ray platforms. These technologies will use AI to improve data collection and analysis, which, in turn, will speed up decision-making

In June 2021, Danaher Corporation launched the Leica Nano workflow, a new live-cell correlative light and electron microscopy (CLEM) workflow solution designed to increase experimental success rates, improve reproducibility, and simplify light and electron microscopy (EM) integration

In April 2019, Zeiss acquired GOM GmbH (Germany), a leading provider of hardware and software for automated 3D coordinate measuring technology

Content Source:

https://www.marketsandmarkets.com/Market-Reports/world-microscopy-399.html

https://www.globenewswire.com/en/news-release/2022/09/19/2518478/0/en/Microscopy-Market-worth-9-5-billion-by-2027-Exclusive-Report-by-MarketsandMarkets.html

[aartichede08]

Future Of North American Oncology Drugs Market: Size, Share, And Forecast 2019–2028

Cancer research is advancing rapidly and new medicines in development take many innovative approaches to fighting the disease. There has been tremendous innovation over the past decade with the emergence of new drugs with very promising efficacy, such as, immunotherapy, along with increasing adoption of precision medicine technologies including companion diagnostics and targeted therapy, as well as advanced monitoring techniques such as liquid biopsy. New treatment options have become available in the past five years, and the surge of innovation is expected to continue due to a robust pipeline of drugs in clinical development by a large and diverse group of pharmaceutical companies. Over 20 tumour types are being treated with one or more of the 70 new cancer treatments that have been launched over the past five years. Furthermore, the impact of these new medicines on patient care is exemplified by the case of the two PD-1 immuno-oncology drugs, whose rapid uptake reflect their remarkable clinical profile and successive expansion of indications.

To know the scope of our report get a sample on https://www.axiommrc.com/request-for-sample/hc1964-north-american-oncology-drugs-market-report

NORTH AMERICAN ONCOLOGY DRUGS MARKET OUTLOOK

The United States has made significant improvements in cancer care, the death rate from cancer in the US has declined steadily over the past 25 years, according to annual statistics reporting from the American Cancer Society. As of 2016, the cancer death rate for men and women combined had fallen 27% from its peak in 1991. This decline translates to about 1.5% per year and more than 2.6 million deaths avoided between 1991 and 2016, it is attributed by the growing number of drugs and technologies available to patients. The direct costs of cancer represent approximately 5% of total direct US health care expenditures. Besides, very expensive cancer treatments such as the new immunotherapies for cancer are more widely available in America than in countries with national healthcare where there are restrictions based on cost/benefit and budget caps.

Moreover, according to the American Cancer Society, in men, the most common cancers diagnosed are prostate, lung, and colorectal cancers. Together, they account for 42% of all cases in men, with prostate cancer alone accounting for nearly 1 in 5 new cases.

NORTH AMERICAN ONCOLOGY DRUGS MARKET SEGMENTAL OVERVIEW

The report analyses the North America oncology drugs market based on therapeutic modules, cancer type and country.

NORTH AMERICAN ONCOLOGY DRUGS MARKET BY THERAPEUTIC MODULES

Based on the therapeutic modules, the oncology drugs market is segmented into chemotherapy, targeted therapy, immunotherapy, hormonal therapy and others. The other therapeutic modules consist of radiation therapy, stem cell transplant, precision medicine among others. Immunotherapy is expected to dominate the North America market due to its high efficacy and less side effects. Monoclonal antibodies such as trastuzumab, bevacizumab and rituximab are potential immunotherapeutic agents that have achieved magnanimous sales. Moreover, over the past few years, targeted cancer therapies have gained significant attention due to their tumour cell specific action in protecting healthy cells from the toxic effects of oncology drugs.

NORTH AMERICAN ONCOLOGY DRUGS MARKET BY CANCER TYPE

By various cancer types, the North America oncology drugs market is segmented into blood cancer, breast cancer, gastrointestinal cancer, prostate cancer, lung cancer, skin cancer and others. Other cancer types majorly include kidney cancer, head & neck cancers, lip cancer, bladder cancer among others. With rapid population growth and aging, the rising prominence of cancer as a leading cause of death partly reflects marked declines in mortality rates of stroke and coronary heart disease, relative to cancer, in many countries.

NORTH AMERICAN ONCOLOGY DRUGS MARKET BY COUNTRY

Various countries included in the North America oncology drugs market are United States, Canada and Mexico. The United States majorly contributed to the oncology drugs market in 2018. Furthermore, Canada is anticipated to be second largest market in oncology drug market. The U.S. region houses companies engaged in the development of oncology drugs. Additionally, the disposable incomes of consumers and health insurance cover for life-threatening diseases in U.S. are very high which increases the affordability of cancer treatment. In recent years, US Food and Drug Administration (USFDA) has taken initiatives to support the growth of oncology drugs market by providing pre-market approval to the drugs, which are in the clinical phase; thus, accelerating the clinical development.

NORTH AMERICAN ONCOLOGY DRUGS MARKET KEY PLAYERS

North America oncology drugs market is led by companies such as, Roche Holding AG (Switzerland), Amgen Inc. (United States), Takeda Pharmaceutical Company Limited (Japan), Bayer AG (Germany), Boehringer Ingelheim GmbH (Germany), Bristol-Myers Squibb Company (United States), Celgene Corporation (United States), Eli Lilly and Company (United States), Johnson & Johnson (United States), Merck & Co., Inc. (United States), Novartis AG (Switzerland), Pfizer Inc. (United States), Sanofi (France) and Teva Pharmaceutical Industries Limited (Israel). In November 2018, Bristol-Myers Squibb Company the U.S. Food and Drug Administration (FDA) approval of Empliciti (elotuzumab) injection for intravenous use in combination with pomalidomide and dexamethasone (EPd) for the treatment of adult patients with multiple myeloma who have received at least two prior therapies, including lenalidomide and a proteasome inhibitor.

Buy now North American Oncology Drugs Market Report https://www.axiommrc.com/buy_now/hc1964-north-american-oncology-drugs-market-report

About Us:

Axiom Market Research & Consulting™ is a full-service market research and data analytics company providing key market intelligence to global companies to take informed business decisions pertaining to their marketing strategy, investments, new product launches, market competition, consumer or end users, social media trends etc. 

Axiom Market Research & Consulting™ offers market research services such as syndicated market research, custom market research, business consulting, and consumer/end user surveys. Under Business to Consumer (B2C) market research offerings, Axiom MRC assists its clients in finding quantitative information/preferences of its brands and services such as, awareness, usages, satisfaction, tracking, ethnicity etc. Axiom MRC offers data collection services through online surveys, social media, data processing and interpretation.

Axiom MRC with its experienced team of research and data analysts, has delivered more than 5000+ Market Research Projects, 3800+ Data Analytics Projects, 1200+ Business Support Projects and has a 800+ Global Client Base. Axiom Market Research & Consulting™ aims to become the preferred market research and data analytics company by providing key market intelligence solutions for client’s business growth.

Contact Us:

Axiom Market Research & Consulting™

3 Germay Dr. Ste 4 - 4666

Wilmington DE 19804

U.S.:- + 1 (845) 875-9786

U.K.:- + 44 (0) 20 3286 9707

Email: sales@axiommrc.com

Website: https://www.axiommrc.com/

Blog: https://industrywatch24.com/

Follow On

LinkedIn: https://www.linkedin.com/company/axiom-market-research-and-consulting/

Twitter:  https://twitter.com/AxiommrcCom

[soumyafwr]

https://www.cienciared.es/blogs/222493/Immuno-Oncology-Market-Size-Analysis-and-Forecast-2031

Immuno-Oncology Market Size, Analysis and Forecast 2031

[databrigemarketresearchreports]

Immuno-Oncology Clinical Trials Market Outlook, Research, Trends and Forecasts to 2029

The market analysis of Immuno-Oncology Clinical Trials market research report provides an examination of various market segments that are supposed to witness the fastest development amid the estimated forecast frame. A comprehensive market research has been conducted in this report which puts a light on the challenges, market structures, opportunities, driving forces, scope, and competitive landscape for the business. The best tools have been adopted to generate this report which is SWOT analysis and Porter’s Five Forces analysis. This market report is truly a key to achieve the new horizon of success. Immuno-Oncology Clinical Trials is a professional and exhaustive report which focuses on primary and secondary drivers, market share, leading segments and geographical analysis. In Immuno-Oncology Clinical Trials market document, a market study and overview is carried out by taking into account market drivers, market restraints, opportunities and challenges for a particular business. Geographical scope of the products is also taken into consideration methodically for the major global areas such as Asia, North America, South America, and Africa. This helps delineate strategies for the product distribution in those areas. The market report estimates the size of the market with respect to the information on key retailer revenues, development of the industry by upstream and downstream, industry progress, key companies, key developments, along with market segments and application. The superior Immuno-Oncology Clinical Trials market report is presented with a full devotion and dedication to the clients that extend their reach to success. Ask for Sample Report at https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immuno-oncology-clinical-trials-market

Some of the market players studied in this report are:

Olympus Corporation, KLS Martin Group, B. Braun Melsungen AG, Medtronic, OmniGuide Holdings, Inc., biolitec AG, Intuitive Surgical, Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, Scanlan International, Getinge AB, and Johnson & Johnson Private Limited, among others.

 The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

On the basis of phase, the     immuno-oncology clinical trials market is segmented into phase I, phase     II, phase III, and phase IV.

On the basis of design, the     immuno-oncology clinical trials market is segmented into interventional     trials, observational trials, and expanded access trials.

On the basis of indication, the     immuno-oncology clinical trials market is segmented into solid tumours,     and hematological cancer.

Topical Retinoid Speak to Analyst https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-immuno-oncology-clinical-trials-market The report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Immuno-Oncology Clinical Trials market.

Product Development/Innovation: Detailed insights on the upcoming technologies, RD activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Market Development: Comprehensive information about emerging markets. This report analyzes the market for various segments across geographies.

Market Diversification: Exhaustive information about new products, untapped geographies, recent developments, and investments in the Global Immuno-Oncology Clinical Trials market.

Why should buy this report?

·         Provides in depth research analysis of the overall Immuno-Oncology Clinical Trials market. which can help save time for start-up businesses related to the Immuno-Oncology Clinical Trials Market.

·         The Immuno-Oncology Clinical Trials markets latest news, forecast analysis as well as the key competitors of the market are easily available with all the necessary information.

·         The Immuno-Oncology Clinical Trials report comprises of graphs, pie charts and other representations that can help the reader understand the information at a glance.

·         Through the Immuno-Oncology Clinical Trials report the manufacturers can understand the consumer behaviour, business segments as well as sell products-based information provided.

Request for Customization https://www.databridgemarketresearch.com/customization/global-immuno-oncology-clinical-trials-market

Thank you for reading our report. For further inquiry, please get in touch with us. Our team will ensure the report is customized to meet your requirements.

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818 Email: Sopan.gedam@databridgemarketresearch.com 

[databridgemarket456]

The immuno-oncology (IO) market is expected to witness market growth at a rate of 8.90% in the forecast period of 2022 to 2029. Data Bridge Market Research report on the immuno-oncology (IO) market provides analysis and insights regarding the various factors expected to be prevalent throughout the forecast period while providing their impacts on the market’s growth. 

[marketresearch-articles]

Immunoassay Reagents and Devices Market Size, Exclusive Research Report by The Insight Partners

Immunoassay Reagents and Devices Market is grow at a CAGR 4.9% in the forecast 2021 to 2028.

Immunoassay Reagents and Devices Market Scope and Size

·        On the basis of product, the immunoassay reagents and devices market is segmented into reagents & kits and analyzers. In 2021, reagents & kits segment is dominating due to its higher usage in drug development as well as in disease detection.

·        On the basis of platform, the immunoassay reagents and devices market is segmented into chemiluminescence immunoassays, fluorescence immunoassays, enzyme immunoassay, radioimmunoassays and others. In 2021, enzyme immunoassay segment is dominating the market because of its advantages such as ease in performing test, accurate result and many others.

·        On the basis of technique, the immunoassay reagents and devices market is segmented into enzyme-linked immunosorbent assays, rapid tests, enzyme-linked immunospot, western blotting, immuno-PCR and other techniques. In 2021, enzyme-linked immunosorbent assays segment is dominating because it is highly sensitive, simple to perform, offer accurate result for any disease detection or in any drug development.

·        On the basis of specimen type, the immunoassay reagents and devices market is segmented into saliva, urine, blood and others. In 2021, blood segment is dominating the market because antigen can be easily detected from the blood.

·        On the basis of application, the immunoassay reagents and devices market is segmented into infectious diseases, oncology and endocrinology, bone & mineral disorders, cardiology, hematology & blood screening, autoimmune disorders, toxicology, neonatal screening and other applications. In 2021, oncology and endocrinology segment is dominating because of high incidence rate worldwide which can be detected easily with the use of immunoassays.

Get the sample copy of Report https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-immunoassay-reagents-and-devices-market

Global Immunoassay Reagents and Devices Market Country Level Analysis

Global immunoassay reagents and devices market is analyzed and market size information is provided by the country, product, platform, technique, specimen type, application and end user as referenced above.

 The countries covered in the global immunoassay reagents and devices market report are the U.S., Canada, Mexico, Germany, Italy, France, U.K., Spain, Russia, Netherlands, Switzerland, Belgium, Turkey, rest of Europe, China, Japan, India, Australia, Singapore, Indonesia, Thailand, South Korea, Malaysia, Philippines, rest of Asia-Pacific, Brazil, Argentina, rest of South America, Saudi Arabia, South Africa, Egypt, UAE, Israel and rest of Middle East and Africa.

Immunoassay Reagents and Devices Market research report indicates that the global Immunoassay Reagents and Devices Market is expected to surge at a steady rate in the coming years. The report provides a comprehensive review of the global market. Analysts have identified the key drivers and restraints in the overall market. The historical milestones achieved by the global market and emerging trends have also been studied in this report. Adopting such market research report is becoming very essential for the businesses as it supports with the better decision making, revenue generation, prioritizing market goals and profitable business.

 The report is objective in nature but includes valuable comments by subject-matter experts. The Immunoassay Reagents and Devices Market research report authenticates and affirms the findings listed by the research analysts. The investigative approach of the research report allows the readers to get a detailed understanding of the finest nuances affecting the market dynamics. This report opens a discussion about the changing economy, governing policies, and political shifts that are expected to shape the market. Moreover, the report assists you in figuring out brand awareness, market landscape, possible future issues, industry trends and customer behaviour which ultimately leads to refined business strategies.

MAJOR TOC OF THE REPORT

Chapter One: Immunoassay Reagents and Devices Market Overview

Chapter Two: Manufacturers Profiles

Chapter Three : Immunoassay Reagents and Devices Market Competition, by Players

Chapter Four: Global Immunoassay Reagents and Devices Market Market Size by Regions

Chapter Five: North Immunoassay Reagents and Devices Market by Countries

Chapter Six: Europe Immunoassay Reagents and Devices Market Revenue by Countries

Chapter Seven: Asia-Pacific Immunoassay Reagents and Devices Market Revenue by Countries

Chapter Eight: South Automotive Immunoassay Reagents and Devices Market Revenue by Countries

Chapter Nine: Middle East and Immunoassay Reagents and Devices Market Revenue Equipment by Countries

Chapter Ten: Global Immunoassay Reagents and Devices Market Segment by Type

Chapter Eleven: Global Immunoassay Reagents and Devices Market by Application

Get TOC Details:   https://www.databridgemarketresearch.com/toc/?dbmr=global-immunoassay-reagents-and-devices-market

major companies dealing in the global immunoassay reagents and devices market report are F. Hoffmann-La Roche Ltd, Siemens, Randox Laboratories Ltd., Abbott, Bio-Rad Laboratories, Inc., Merck KGaA, Beckman Coulter, Inc. (a subsidiary of Danaher), Sysmex Corporation, bioMérieux SA, Thermo Fisher Scientific, Inc., BD, Shenzhen Mindray Bio-Medical Electronics Co., Ltd., DiaSorin S.p.A, Ortho Clinical Diagnostics, QIAGEN, Quidel Corporation, BioCheck, Inc., Bio-Techne, PerkinElmer Inc., Agilent Technologies, Inc., Luminex Corporation, MESO SCALE DIAGNOSTICS, LLC among other domestic and global players. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Access Full Report   https://www.databridgemarketresearch.com/reports/global-immunoassay-reagents-and-devices-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports@

Medical Waste Management Market

Yeast Protein Expression Service Market

[researchupdates]

2021-2027 Flow Cytometry Market Trending Technologies, Remarkable Developments

Overview of Global Flow Cytometry Market:

The Market dynamics study of an influential Flow Cytometry report demonstrates the scope of the various commercial possibilities over the coming years and the positive revenue forecasts in the years ahead. Important industry trends, Market size, Market share estimates are analysed and mentioned in the industry analysis report. It also studies the key Markets and mentions the different regions i.e. the topographical spread of the business. The report gives helpful insights which assist while launching a new product. The large scale Flow Cytometry Market report helps business in knowing its Market share over various time periods, transportation, storage, and supply requirements of its products.

Under competitive Market share evaluation, it suggests that key players dominate the operations in the industry attributable to their strong geographical reach and huge production facilities. Global Flow Cytometry Market report serves to be an ideal solution for better understanding of the Market. It is helpful in finding out the size of the Market for specific products. These major players operating in this Market are in strong competition in terms of technology, innovation, product development, and product pricing. The Market study aids in making sales forecasts for its products and thereby, establishing harmonious adjustment between demand and supply of its products.

Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-flow-cytometry-market .

The Global Flow Cytometry Market is expected to USD 7.51 Billion by 2027 growing at a CAGR of 8.56% in the forecast period of 2020 to 2027.

The major key factors driving the growth of the Global Flow Cytometry Market are increasing public-private initiatives in the field of immunology and immuno-oncology research, Increasing incidence and prevalence of HIV/AIDS and cancer, availability of application-specific products, growing adoption of flow cytometry techniques in research and academia, increasing incorporation of AI platforms in flow cytometry workflows and advancements in flow cytometry software along with technological advancement.

Top Leading Key Manufacturers are: Bio-Rad Laboratories, Inc., Miltenyi Biotec Sysmex Partec GmbH, BIOMÉRIEUX, Mechatronics, Apogee Flow Systems Ltd., Stratedigm, Inc., Sony Biotechnology Inc., BD., Thermo Fisher Scientific Inc., Merck KGaA, ACEA BIO, Agilent Technologies, Luminex Corporation., Enzo Life Sciences, Inc., Beckman Coulter, Inc., Takara Bio Inc and others. New product launches and continuous technological innovations are the key strategies adopted by the major players.

In terms of the geographic analysis, North America dominates the flow cytometry market due to presence of supportive government reforms for the development of advanced technologies for molecular diagnostics, presence of a large number of clinical research labs and major pharmaceuticals in the U.S., while APAC is expected to grow at the highest growth rate in the forecast period of 2020 to 2027 due to supportive government funding for the biotech industry development and presence of untapped opportunities, constantly improving healthcare infrastructure, rapid economic development, and rising patient awareness levels.

Access Complete Report Here: https://www.databridgemarketresearch.com/reports/global-flow-cytometry-market .

[rohans18]

Immuno-Oncology Clinical Trials Market Market CAGR, Trends, Top Players, Analysis, Industry Size - Forecast 2029

Global Immuno-Oncology Clinical Trials Market, By Phase (Phase I, Phase I, Phase III, Phase IV), Design (Interventional Trials, Observational Trials, Expanded Access Trials), Indication (Solid Tumours, Hematological Cancer), Country (U.S., Canada, Mexico, Germany, Italy, U.K., France, Spain, Netherland, Belgium, Switzerland, Turkey, Russia, Rest of Europe, Japan, China, India, South Korea, Australia, Singapore, Malaysia, Thailand, Indonesia, Philippines, Rest of Asia- Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Egypt, Israel, Rest of Middle East and Africa) Industry Trends and Forecast to 2029

The consistent Immuno-Oncology Clinical Trials Market market report analyzes many points that help businesses to solve the toughest questions in less time. The major topics of this business report are global growth trends, market share by manufacturers, market size by type, market size by application, production by region, consumption by region, company profiles, market forecast, value chain and sales channels analysis, opportunities & challenges, threat and affecting factors. The report gives market definition in the form of market driving factors and market restraints which helps estimating the demand of particular product depending on several aspects. Immuno-Oncology Clinical Trials Market market survey report studies the global market status and forecast, categorizes the global market size, market value & market volume by key players, type, application, and region.

Key Players

Some of the major players operating in the immuno-oncology clinical trials market report are Olympus Corporation, KLS Martin Group, B. Braun Melsungen AG, Medtronic, OmniGuide Holdings, Inc., biolitec AG, Intuitive Surgical, Bristol Myers Squibb Company, Novartis AG, F. Hoffmann-LA Roche Ltd., GlaxoSmithKline Plc., Eli Lilly and Company, Scanlan International, Getinge AB, and Johnson & Johnson Private Limited, among others.

 Browse More Info @ https://www.databridgemarketresearch.com/reports/global-immuno-oncology-clinical-trials-market

One of the principal objectives of a high-ranking Immuno-Oncology Clinical Trials Market industry report is to analyze and study the global sales, value, status, and forecast. The market report also analyzes the global and key regions market potential and advantage, opportunity and challenge, restraints and risks. The report assists to define, describe and forecast the market by type, application and region. It estimates the region that is foretold to create the most number of opportunities in the global Immuno-Oncology Clinical Trials Market market. This market research report comprises of estimations of CAGR values which are quite significant and aids businesses to decide upon the investment value over the time period. An insightful Immuno-Oncology Clinical Trials Market market report assists clients to stay ahead of the time and competition.

Key questions answered in the report:

Which product segment will grab a lion’s share?

Which regional market will emerge as a frontrunner in coming years?

Which application segment will grow at a robust rate?

Report provides insights on the following pointers:

Market Penetration: Comprehensive information on the product portfolios of the top players in the Immuno-Oncology Clinical Trials Market Market.

Product Development/Innovation: Detailed insights on the upcoming technologies, R&D activities, and product launches in the market.

Competitive Assessment: In-depth assessment of the market strategies, geographic and business segments of the leading players in the market.

Table Of Content

Part 01: Executive Summary

Part 02: Scope Of The Report

Part 03:  Global Market

Part 04: Global Market Sizing

Part 05: Global Market Segmentation By Product

Part 06: Five Forces Analysis

 About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: sales@databridgemarketresearch.com

[sciencespies]

50 Over 50: How This Iranian Immigrant’s Vision Could Revolutionize Cancer Treatment

https://sciencespies.com/news/50-over-50-how-this-iranian-immigrants-vision-could-revolutionize-cancer-treatment/

50 Over 50: How This Iranian Immigrant’s Vision Could Revolutionize Cancer Treatment

As adults, few of us are doing what we wanted to grow up to be as children. Reality and bills and basic human limitations persuade us away from our cowboy ninja and time-traveling detective dreams. Fortunately, this isn’t the case for Helen Sabzevari. “I think the very first time I recognized I wanted to do what I’m doing currently, was when I was 12 years old,” she says, recalling to Forbes how she was mesmerized by a pre-teen biology lesson on cancer. 

Forty-seven years later, Sabzevari is CEO of Precigen, a biopharmaceutical company developing cutting edge treatments for a number of different diseases, including type 1 diabetes and certain forms of cancer. It’s here that Sabzevari, 59, is bringing her lifetime of experience in cancer research to realize a vision of immunotherapies that are both more effective and easier to scale than what’s on the market now.    

One of the biggest innovations in cancer treatments was the development of CAR-T cell therapy. These engineered immune cells are delivered to the body through specially designed viruses, where they target molecular changes typically seen in cancers and attack. The first such treatment was approved by the FDA in 2017, and four others have been approved since. 

CAR-T therapies have shown great success against certain cancers but they also have limitations: they don’t work well against solid tumors, and so are generally used against leukemia and other blood cancers. They’re also expensive: a course of CAR-T therapy can cost over four hundred thousand dollars, according to the Centers for Medicare and Medicaid Services.

Sabzevari’s vision is a different approach: developing what her company calls “Ultra CAR-T.” In this therapy, T-cells fighting cancer within a patient are isolated, and the genes triggering their production are introduced into plasmid DNA, a type of DNA commonly found in bacteria. The plasmid DNA is then engineered to produce T-cells that are even more potent against cancer cells. The results are then reintroduced to the body along with an IL-15 cytokine membrane, where they go to work fighting cancer. By using plasmids instead of viruses, Ultra CAR-T cells avoid the risk that the body may mistake the treatment for an invading cell that needs to be fought off, improving safety. 

Additionally, plasmid DNA can be scaled and manufactured much more cheaply and Precigen uses a sophisticated, proprietary system to ensure quality control—its manufacturing system received FDA clearance in fall 2020. It’s also fast: if a patient has their blood drawn in the morning, the T-cells can be isolated and Ultra CAR-T cells manufactured and ready to deliver back the next day, Sabzevari says. 

Another advantage of Ultra CAR-T cells is persistence. Whereas CAR-T cells only stick around the body for 2-3 weeks, preliminary data suggests Ultra CAR-T cells can stick around for months, meaning that they can attack solid tumors. This broadens the scope of cancers that could be treated with the therapy. And if it turns out there’s something going wrong with the treatment, it comes packaged with a genetic “kill switch” that gets rid of the cells.

The company’s first two Ultra CAR-T treatments are currently in phase one clinical trials, but preliminary data have so far been positive. This has made the therapy attractive not only to patients but also Wall Street. The company’s treatment approach has the potential to “disrupt current approaches with lower cost of goods, next-day delivery, and extension of efficacy into solid tumors,” Wells Fargo analysts wrote in a recent research note. 

And the woman behind that disruption? She’s been preparing for this her whole life. 

Born in Iran, Helen Sabzevari excelled in her studies, especially when it came to science and biology. Due to the country’s revolution in 1979, her family sent her to live in the United States. Thanks to her advanced work in high school in her home country, she was able to enroll in City University of New York right away. While she was pursuing her undergraduate and graduate studies, she volunteered at Sloan Kettering and the Brookhaven National Laboratory. 

After getting her PhD in cell and molecular immunology at the Scripps Research Institute, she remained at that institution to pursue her postdoctoral studies in cancer immunotherapy, where she explored the intersection of the immune system and cancer — an area where researchers are ubiquitous today but not so much back then. “I was one of the very, very few postdocs in the field at that time,” she recalls.  

She went on to do a second postdoc at Scripps exploring autoimmunity; then, in 1998, she joined the National Institutes of Health, leading an immunology group at National Cancer Institute. Her team focused on the design and development of new types of cancer treatments, include vaccines and immunotherapies. In that role, she says, “we were able to learn how to translate what we were developing in research for the patients in the clinic.”  

A job at Merck as a senior VP in immuno-oncology and global head of immunotherapy followed, in 2008. “That was a very difficult decision,” she says of choosing to leave the NCI. But as important as she felt her work at NCI was, it didn’t involve creating the drugs that would actually get to patients. “I really wanted to learn that part and bring it back to be a bridge between academia and pharma,” she says. 

After six years at Merck, Sabzevari cofounded and became chief science officer of Compass Therapeutics, a Cambridge, MA-based biotechnology startup developing antibody therapies for cancer. The move to biotechnology startups from big pharma, she says, was to get closer to the action. “I wanted to move to a smaller biotech on the cutting edge of what I considered the next innovative area in immuno-oncology,” she says. “Which was gene and cell therapy.”

She spent three years at Compass Therapeutics before signing on to Precigen as head of R&D in 2017, and became president a few months later. At the time, Precigen was a subsidiary of Intrexon Corporation but in January 2020, Intrexon merged with the Precigen subsidiary, changed its name and Sabzevari took the reins as president and CEO. Since then, the company has not only been pursuing cancer therapies, but also autoimmune disorders such as Type 1 diabetes. 

To engage type 1 diabetes specifically, the company has developed a platform where genetically-modified gut bacteria are introduced to a patient. The bacteria then produce immune cells that prevent the immune system from attacking its own pancreas. Phase one trial data for that treatment is also positive so far, and trials are moving on to phase two. The company is using the same bacteria platform to tackle other autoimmune diseases like Celiac disease. 

In Sabzevari’s first year as CEO, the company saw $103 million in revenue, a 14% increase over 2019. A little over $20 million of that came from licensing and collaboration agreements, which is typical for an early-stage biotechnology company. The rest of the company’s revenue comes from two subsidiaries that remained after the change from Intrexon to Precigen: Trans Ova, which provides genetic analysis for animal husbandry, and Exemplar, which produces genetically modified animal models for medical research. 

Moving forward this year, the company plans to continue advancing its pipeline of cancer and autoimmune treatments, with more clinical data expected to be reported in the late fall, though it’s still a few years away from getting products to market.  For her part, Sabzsevari is elated with the positive results she’s seen so far. Not for the success it brings to the company, but because of the hope it brings to patients. The way she sees it, “failure is very difficult to take because it means failure, basically, in extending somebody’s life.” That viewpoint is what drives her to keep her company’s work moving forward.

“The moment that this becomes a business to me and it’s not personal, that’s the moment I step down,” she says. “Because you can only push with the speed that we are pushing when you take it personally. For me, this has been personal all my life.”

#News

[riyadbmr21]

Flow Cytometry Market In-Depth Qualitative Insights & Future Growth Analysis 2021-2027

“Flow Cytometry Market” 2021 report is designed by detailed investigation procedure to collect all the necessary data. This report contains a brief profile of leading players in the industry along with their future plans and current developments. Further, the report considers the revenue generated from the market analysis and opportunity analysis to estimate the market size. The report initiates with the basic market outlook and structure along with a forecast of the various segments and sub-segments.

In addition, the analysis sheds light on restraints and constraints in the Flow Cytometry market that may potentially become barriers while the sector is likely to attain significant revenue. Flow cytometry market is expected to gain market growth in the forecast period of 2020 to 2027. Data Bridge Market Research analyses the market to account to USD 7.51 billion by 2027 growing at a CAGR of 8.56% in the above-mentioned forecast period. The growing public-private initiatives in the field of immunology and immuno-oncology research will help in driving the growth of the flow cytometry market.

Have a fresh look with latest Trend and Outlook@ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-flow-cytometry-market

The preliminary study highlights essential players as well as types, applications, and major regions. The report provides access to information divided by company type and sizes. Our authorized team of experts, researchers, and advisors has taken extra efforts in utilizing market data resources along with practices and tools to perform research and analysis on study information. Afterward, it covers the industry requirements such as profit, capacity, distribution, demand growth speed and prediction, production, price, and prediction. In the next section, the report highlights the drivers and restraints affecting the global Flow Cytometry market. The study incorporates the different divisions of the market by type, application, and district.

Major Players Covered in this report:

Bio-Rad Laboratories, Inc., Miltenyi Biotec Sysmex Partec GmbH, BIOMÉRIEUX, Mechatronics, Apogee Flow Systems Ltd., Stratedigm, Inc., Sony Biotechnology Inc., BD., Thermo Fisher Scientific Inc., Merck KGaA, ACEA BIO, Agilent Technologies.

Key Questions Answered in the Report:

What is the current scenario of the Global Flow Cytometry Market? How is the market going to prosper throughout the next few years?

What are the emerging technologies that are going to profit the market?

What is the historical and the current size of the Global Flow Cytometry Market?

Which segments are the fastest growing and the largest in the market? What is their market potential?

What are the driving factors contributing to market growth during the short, medium, and long term?

Ask more details or request custom reports to our experts@ https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-flow-cytometry-market

Strategic points covered by TOC:

Chapter 1: The scope of products driving the market, the market risks, the market overview, and the market opportunities in the global Flow Cytometry market.

Chapter 2: Assessment of Top Manufacturers in the Worldwide Flow Cytometry Market Consisting of Revenue, Sales, and Product Price

Chapter 3: Show Competitiveness Among Top Manufacturers Along with Market Share, Revenue, and Sales

Chapter 4: Analysis of Global Flow Cytometry Market by Region, Market Share, Forecast Period Revenue, and Sales

Chapters 5, 6, 7, 8, and 9: Assess Markets by Segment, Country, and Manufacturer, and Assess Revenue Shares and Sales by Top Country in These Different Regions.

Key Reasons to Purchase the Market Report:

Gain perceptive analysis of the analysis of Flow Cytometry market based on product type, end-use, market opportunities, and regional demand by 2027.

Systematic data review and meta-analysis of the Flow Cytometry market based on global manufacturers and regions.

Understand the maximum affecting driving and preventive strengths in the market and its influence on the global market.

Identify hidden opportunities of Flow Cytometry market with globally rising CAGR forecast till 2027.

Calculate the key problems, product developments, and solutions to manipulate the progress threat.

Access Full Report@ https://www.databridgemarketresearch.com/reports/global-flow-cytometry-market

About Us:

Data Bridge Market Research set forth itself as an unconventional and neoteric Market research and consulting firm with unparalleled level of resilience and integrated approaches. We are determined to unearth the best market opportunities and foster efficient information for your business to thrive in the market

Contact:

Data Bridge Market Research

Tel: +1-888-387-2818

Email: Sopan.gedam@databridgemarketresearch.com

Browse Related Reports@

Blood Bank Refrigerators Market

Esophagoscopes and Gastroscopes Market

Fox–Fordyce Disease Treatment Market